Overview of clinical, immunophenotypical, and cytogenetic (conventional and/or molecular cytogenetic) characteristics of preBLL samples studied
| Case . | Age, y/sex . | Site* . | Diagnosis . | Morphology . | Time to relapse . | Conventional and/or molecular cytogenetic characteristics . | Immunophenotype . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IG-MYC status . | BCL2 . | BCL6 . | Karyotype . | TdT . | CD34 . | CD10 . | BCL6 . | CD19 . | CD20 . | sIg . | Ki-67 . | ||||||
| 1 ID† | 6/M | BM | B-ALL | BL-like | 8 mo | IGH-MYC | − | − | 47,XY,+idic(1)(p12),t(8;14)(q24;q32)[1]/ 47,idem,del(15)(q24)[22]/46,XY[2] | + | − | + | NA | + | +/−, weak | − | NA |
| 1 R† | BM | B-ALL | BL-like | IGH-MYC | − | − | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8, t(8;14)(q24;q32)x2,+14,del(15)(q24)[25] | NA | − | + | NA | NA | + | − | NA | ||
| 2 ID | 75/M | Skin | B-LBL | NA | — | IGH-MYC | − | − | NA | + | − | + | NA | + | − | − | 80% |
| 3 ID | 69/M | PB | B-ALL | NA | — | IGH-MYC | − | − | 46,XY,+1,+1,der(1;13)(q10;q10), der(1;15)(q10;q10),t(8;14)(q24;q32)[20] | + | NA | NA | NA | − | +/− | NA | 100% |
| 4 ID | 13/M | BM | B-ALL | L2/3‡ | 14 mo | IGK-MYC | − | − | 47,XY,t(2;8)(p12;q24),+21[11] | + | NA | + | NA | + | − | − | NA |
| 4 R | BM | NA | NA | NA | NA | NA | + | NA | − | − | + | +/− | − | NA | |||
| 5 ID | 3/M | BM | B-ALL | L3‡ | — | IGH-MYC | − | − | 47,XY,trp(1)(q21q43),t(8;14)(q24;q32), +mar[10] | + | − | + | − | + | + | − | NA |
| 6 ID | 11/F | BM | B-ALL | L3‡ | — | IGL-MYC | − | − | 46,XX,t(8;22)(q24;q11)[20] | + | − | + | − | + | − | NA | NA |
| 7 ID§ | 70/M | BM | B-ALL | BL-like | — | IGH-MYC | − | − | NA | + | − | + | − | + | − | + | High |
| 8 ID§ | 56/M | BM | B-ALL | BL-like | — | IGH-MYC | − | − | NA | +/− | − | + | − | + | −/+ | NA | 95% |
| 9 ID‖ | 44/M | LN | B-LBL | NA | — | IGH-MYC | − | − | NA | + | − | + | − | NA | + | NA | ∼95% |
| 10.1 ID | 43/M | BM | B-LBL | NA | — | IGH-MYC | + | − | 47,XY,t(8;14)(q24;q32),t(14;18)(q32;q21), der(16)t(1;16)(q21;p13.3),+21[16]/ 46,XY[4] | + | NA | + | NA | NA | NA | NA | NA |
| 10.2 ID | BM | B-LBL | NA | — | IGH-MYC | + | − | NA | NA | NA | + | − | NA | + | NA | NA | |
| 11 ID | 13/F | BM | B-ALL | NA | 142 d | IGL-MYC | + | − | 48,XX,i(1)(q10),+7,t(8;22)(q24;q11), t(14;18)(q32;q21)[10] | + | − | + | NA | + | NA | NA | NA |
| 11 R | BM | B-ALL | NA | IGL-MYC | + | − | 48,XX,i(1)(q10),+7,t(8;22)(q24;q11), t(14;18)(q32;q21)[20] | NA | NA | NA | NA | NA | NA | NA | NA | ||
| 12 ID¶ | 21/M | BM | B-ALL | L2‡ | — | IGH-MYC | + | − | 46,XY,t(8;14)(q23;q32),t(14;18)(q32;q21)[3]/46,XY,idem,t(13;17)(q12;p11),-17[7]/ 46,XY,idem,+t(13;13)(p11;q13), t(13;17)(q12;p11),-17[2]/46,XY[2] | + | NA | NA | NA | NA | NA | NA | NA |
| 380 cell line# | 15/M | PB | B-ALL | L2‡ | — | IGH-MYC | + | − | 46(43-47)<2n>XY,-14,t(8;14;18)(q24; q32;q21), +der(14)t(8;14;18)(q24;q32; q21) 1.8% polyploidy | + | − | + | NA | + | + | − | NA |
| Case . | Age, y/sex . | Site* . | Diagnosis . | Morphology . | Time to relapse . | Conventional and/or molecular cytogenetic characteristics . | Immunophenotype . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IG-MYC status . | BCL2 . | BCL6 . | Karyotype . | TdT . | CD34 . | CD10 . | BCL6 . | CD19 . | CD20 . | sIg . | Ki-67 . | ||||||
| 1 ID† | 6/M | BM | B-ALL | BL-like | 8 mo | IGH-MYC | − | − | 47,XY,+idic(1)(p12),t(8;14)(q24;q32)[1]/ 47,idem,del(15)(q24)[22]/46,XY[2] | + | − | + | NA | + | +/−, weak | − | NA |
| 1 R† | BM | B-ALL | BL-like | IGH-MYC | − | − | 53,XY,+X,+Y,+idic(1)(p12),+6,+7,+8, t(8;14)(q24;q32)x2,+14,del(15)(q24)[25] | NA | − | + | NA | NA | + | − | NA | ||
| 2 ID | 75/M | Skin | B-LBL | NA | — | IGH-MYC | − | − | NA | + | − | + | NA | + | − | − | 80% |
| 3 ID | 69/M | PB | B-ALL | NA | — | IGH-MYC | − | − | 46,XY,+1,+1,der(1;13)(q10;q10), der(1;15)(q10;q10),t(8;14)(q24;q32)[20] | + | NA | NA | NA | − | +/− | NA | 100% |
| 4 ID | 13/M | BM | B-ALL | L2/3‡ | 14 mo | IGK-MYC | − | − | 47,XY,t(2;8)(p12;q24),+21[11] | + | NA | + | NA | + | − | − | NA |
| 4 R | BM | NA | NA | NA | NA | NA | + | NA | − | − | + | +/− | − | NA | |||
| 5 ID | 3/M | BM | B-ALL | L3‡ | — | IGH-MYC | − | − | 47,XY,trp(1)(q21q43),t(8;14)(q24;q32), +mar[10] | + | − | + | − | + | + | − | NA |
| 6 ID | 11/F | BM | B-ALL | L3‡ | — | IGL-MYC | − | − | 46,XX,t(8;22)(q24;q11)[20] | + | − | + | − | + | − | NA | NA |
| 7 ID§ | 70/M | BM | B-ALL | BL-like | — | IGH-MYC | − | − | NA | + | − | + | − | + | − | + | High |
| 8 ID§ | 56/M | BM | B-ALL | BL-like | — | IGH-MYC | − | − | NA | +/− | − | + | − | + | −/+ | NA | 95% |
| 9 ID‖ | 44/M | LN | B-LBL | NA | — | IGH-MYC | − | − | NA | + | − | + | − | NA | + | NA | ∼95% |
| 10.1 ID | 43/M | BM | B-LBL | NA | — | IGH-MYC | + | − | 47,XY,t(8;14)(q24;q32),t(14;18)(q32;q21), der(16)t(1;16)(q21;p13.3),+21[16]/ 46,XY[4] | + | NA | + | NA | NA | NA | NA | NA |
| 10.2 ID | BM | B-LBL | NA | — | IGH-MYC | + | − | NA | NA | NA | + | − | NA | + | NA | NA | |
| 11 ID | 13/F | BM | B-ALL | NA | 142 d | IGL-MYC | + | − | 48,XX,i(1)(q10),+7,t(8;22)(q24;q11), t(14;18)(q32;q21)[10] | + | − | + | NA | + | NA | NA | NA |
| 11 R | BM | B-ALL | NA | IGL-MYC | + | − | 48,XX,i(1)(q10),+7,t(8;22)(q24;q11), t(14;18)(q32;q21)[20] | NA | NA | NA | NA | NA | NA | NA | NA | ||
| 12 ID¶ | 21/M | BM | B-ALL | L2‡ | — | IGH-MYC | + | − | 46,XY,t(8;14)(q23;q32),t(14;18)(q32;q21)[3]/46,XY,idem,t(13;17)(q12;p11),-17[7]/ 46,XY,idem,+t(13;13)(p11;q13), t(13;17)(q12;p11),-17[2]/46,XY[2] | + | NA | NA | NA | NA | NA | NA | NA |
| 380 cell line# | 15/M | PB | B-ALL | L2‡ | — | IGH-MYC | + | − | 46(43-47)<2n>XY,-14,t(8;14;18)(q24; q32;q21), +der(14)t(8;14;18)(q24;q32; q21) 1.8% polyploidy | + | − | + | NA | + | + | − | NA |
+, positive; −, negative; −/+, negative with positive parts; BM, bone marrow; LN, lymph node; NA, not available; PB, peripheral blood; sIg, surface immunoglobulin; TdT, terminal deoxynucleotidyltransferase.
Site indicates localization of the tumor analyzed in this study.
Case 1 published by Roug et al.12
Morphology according to French-American-British classification.
Cases 7 and 8 published by Li et al.11
Case 9 reported to be HIV+.
Case 12 published by Mufti et al.6
Cell line 380 described by Pegoraro et al.13